Protalix BioTherapeutics, Inc. (DE) (PLX) News

Protalix BioTherapeutics, Inc. (DE) (PLX): $1.09

-0.01 (-0.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PLX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Filter PLX News Items

PLX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PLX News Highlights

  • For PLX, its 30 day story count is now at 2.
  • Over the past 21 days, the trend for PLX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about PLX are MAA and RARE.

Latest PLX News From Around the Web

Below are the latest news stories about Protalix BioTherapeutics Inc that investors may wish to consider to help them evaluate PLX as an investment opportunity.

Protalix, Chiesi Global file for EU approval of PRX-102 for Fabry disease

Protalix BioTherapeutics (NYSE:PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., submitted an application via centralized procedure to the European Medicines Agency (EMA) for pegunigalsidase alfa (PRX–102) to treat adults with Fabry disease. The Marketing Authorization Application (MAA) is backed by preclinical, clinical and manufacturing data from completed and...

Seeking Alpha | February 24, 2022

Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that there will be two poster presentations regarding the Company's pegunigalsidase alfa or PRX–102 candidate under development for the treatment of Fabry disease at the 18th Annual WORLDSymposium™ 2022, taking

Yahoo | February 3, 2022

Protalix Biotherapeutics: Is It Worth The Wait?

No summary available.

Seeking Alpha | January 7, 2022

Protalix BioTherapeutics Issues 2021 Letter to Stockholders

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.

Yahoo | December 22, 2021

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Shares Bought by Morgan Stanley

Morgan Stanley raised its stake in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) by 3,723,538.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,861,819 shares of the companys stock after acquiring an additional 1,861,769 shares during the period. Morgan Stanleys holdings in Protalix BioTherapeutics []

Dakota Financial News | December 12, 2021

Protalix BioTherapeutics Inc. (AMEX: PLX): Whats Next In 2021?

Protalix BioTherapeutics Inc. (AMEX:PLX) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 6.10% to the previous days close as strong demand from buyers drove the stock to $1.00. Actively observing the price movement in the last trading, the stock closed the session at $0.94, falling within a range of $0.92 Protalix BioTherapeutics Inc. (AMEX: PLX): Whats Next In 2021? Read More »

Stocks Register | November 25, 2021

Protalix BioTherapeutics Inc (PLX): Price Now Near $0.95; Daily Chart Shows Downtrend on 100 Day Basis

The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post Protalix BioTherapeutics Inc (PLX): Price Now Near $0.95; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .

ETF Daily News | November 23, 2021

Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | November 15, 2021

PLX: Third Quarter Update

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 3Q:21 financial and operational results in a November 15, 2021 press release and filing of Form 10-Q . Promulgation of the reports was followed by a pre-market conference call which discussed recent achievements. Operational

Yahoo | November 15, 2021

Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2021 and provided a financial and business update on recent corporate, clinical and regulatory developments.

Yahoo | November 15, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4693 seconds.